Shots: Tyme to receive $20M up front for 10M restricted shares of common stock at $2/share, up to $20M milestones based on meeting @1EPs as OS in TYME-88-Panc pivotal trial […]readmore
Tags : Co-Promotion
Shots: Gilead collaborates with Eisai to distribute & co-promote filgotinib for RA. Gilead will be accountable for manufacturing and approval of filgotinib while Eisai will be responsible for distribution in […]readmore
Shots: Novartis to receive upfront from Sumitomo. Sumitomo to get rights to co-promote Novartis’ Equa and EquMet from July’19 in addition to distribution rights from Nov’19, receiving payment for promotion […]readmore
Shots: Enterome to get $50M upfront plus $640M as milestones payments and future equity investment commitment from Takeda. The companies will jointly co-develop EB8018 and if approved, the product will […]readmore
Shots: Dova Pharmaceuticals to pay Salix Pharmaceuticals, a quarterly fee on the US sales. Salix to deploy ~100 specialists for promotion of Doptelet which is expected to launch in mid-Oct […]readmore